Printer Friendly

Former President and CEO of Incyte Joins Alexion Board of Directors.

M2 PHARMA-September 18, 2017-Former President and CEO of Incyte Joins Alexion Board of Directors

(C)2017 M2 COMMUNICATIONS

- New Haven, Connecticutt-based rare disorders treatment specialist Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) has appointed Paul A. Friedman, M.D. to serve on the its board of directors, the company said.

Friedman succeeds R. Douglas Norby, who has retired as a director following 18 years of service to the company.

Friedman is a veteran of the biotech industry with deep experience in research, and both early and late clinical development.

Over his more than 40-year career, he has established a strong track record of building and leading R and D organisations, successfully expanding their pipelines of assets, overseeing the commercial development of innovative therapeutic products across a range of areas, and building shareholder value.

Friedman served as president and chief executive officer of Incyte Corp. from 2001-2014 where he led a transformation of the business from genomics to a therapeutic focus establishing its foundation as a leader in oncology. He continues to serve on Incyte's board of directors.

Currently, Friedman serves as chairman and chief executive officer of Madrigal Pharmaceuticals, Inc., following its merger with Synta Pharmaceuticals Corp.

In July 2016. Earlier in his career, he held executive and R and D positions with DuPont Pharmaceuticals Research Laboratories, Merck Research Laboratories and Merck Sharp and Dohme Corp.

Friedman received his M.D. from Harvard Medical School and his B.S. in Biology from Princeton University.

Alexion also announced that director Alvin S. Parven advised the board that he does not plan to stand for re-election at the company's next annual meeting of shareholders following 18 years of service as an Alexion director.

The board of directors has retained Spencer Stuart to conduct a search for an additional new director.

Alexion is focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders.

The company has developed and commercializes the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Sep 18, 2017
Words:348
Previous Article:James Cardia to Manage Business Development and Partnering at RXi Pharmaceuticals with Departure of Chief Business Officer Eliseev.
Next Article:Imara Study Shows Favourable Results of IMR-687 in Sickle Cell Disease.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters